Compare Novo Nordisk A/S (NVO) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vale SA — how do they compare? Novo Nordisk A/S trades at $44.89 (market cap $200.69B), while Vale SA trades at $15.44 (market cap $65.56B). The key difference: Novo Nordisk A/S is far larger — about 3.1× Vale SA's market cap, and Vale SA pays the higher dividend (7.65%). Which is the better fit depends on your goals.
| NVO | VALE | |
|---|---|---|
Market Cap | $200.69B | $65.56B |
Sector | Health | Basic Materials |
52-Week High | $63.98 | $17.82 |
52-Week Low | $35.29 | $10.50 |
Enterprise Value | $215.49B | $81.80B |
Dividend Yield | 3.98% | 7.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
VALE trades at $15.56, up 1.9% today, with a bullish technical signal and mixed fundamentals. Recent earnings missed estimates, but cash flow improved to $2.42B in 2025. The company maintains a stable dividend and sees iron ore demand as resilient, per CFO comments on September 9, 2026.
Outlook is cautious due to declining profit margins and rising debt, but analyst consensus suggests modest upside to a $16.25 price target. Risks include commodity price volatility and operational costs, while institutional interest remains steady.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
